Bruker Corporation (BRKR) is a Medical - Devices company in the Healthcare sector, currently trading at $39.90. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of BRKR = $14.00 (-64.9% from the current price, the stock appears overvalued). Analyst consensus target is BRKR = $52 (+30.7% upside).
Valuation: BRKR trades at a trailing Price-to-Earnings (P/E) of -659 (S&P 500 average ~25).
Financials: revenue is $3.4B, +10.9%/yr average growth. Net income is $9M (loss), growing at -45.7%/yr. Net profit margin is -0.3% (negative). Gross margin is 45.6% (-6 pp trend).
Balance sheet: total debt is $2.0B against $2.5B equity (Debt-to-Equity (D/E) ratio 0.83, moderate). Current ratio is 1.73 (strong liquidity). Debt-to-assets is 32.7%. Total assets: $6.2B.
Analyst outlook: 16 / 32 analysts rate BRKR as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 48/100 (Partial), Past 75/100 (Partial), Health 67/100 (Partial), Moat 52/100 (Partial), Future 64/100 (Pass), Income 10/100 (Fail).
